Author

Alfredo J. Lucendo

DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PARTS B AND C OF THE RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY
DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PARTS B AND C OF THE RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

Alfredo J. Lucendo  et al.

EFFECTIVENESS OF FIRST-LINE H. PYLORI ERADICATION THERAPY ACCORDING TO THE DAILY STATIN-USE: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF FIRST-LINE H. PYLORI ERADICATION THERAPY ACCORDING TO THE DAILY STATIN-USE: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2021: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2021: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

COMPARISON OF THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION REGIMENS BETWEEN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
COMPARISON OF THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION REGIMENS BETWEEN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

DIFFERENCES OF HELICOBACTER PYLORI DIAGNOSTICS AND TREATMENTS IN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
DIFFERENCES OF HELICOBACTER PYLORI DIAGNOSTICS AND TREATMENTS IN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group
Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group

Alfredo J. Lucendo  et al.

ROLE OF THE PROTON PUMP INHIBITORS IN HELICOBACTER PYLORI ERADICATION: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROLE OF THE PROTON PUMP INHIBITORS IN HELICOBACTER PYLORI ERADICATION: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

ROLE OF COMPLIANCE IN HELICOBACTER PYLORI TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROLE OF COMPLIANCE IN HELICOBACTER PYLORI TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

STRUCTURAL ALTERATIONS OF COLONIC MICROVILLI IN MICROSCOPIC COLITIS AND RESTORATION BY ORAL BUDESONIDE
STRUCTURAL ALTERATIONS OF COLONIC MICROVILLI IN MICROSCOPIC COLITIS AND RESTORATION BY ORAL BUDESONIDE

Alfredo J. Lucendo  et al.

ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

TRENDS IN THE PRESCRIPTION OF EMPIRICAL TREATMENTS AND THEIR EFFECTIVENESS IN NAÏVE PATIENTS OVER 10 YEARS (2013-2022) IN EUROPE: DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
TRENDS IN THE PRESCRIPTION OF EMPIRICAL TREATMENTS AND THEIR EFFECTIVENESS IN NAÏVE PATIENTS OVER 10 YEARS (2013-2022) IN EUROPE: DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Alfredo J. Lucendo  et al.

EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 8,000 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 8,000 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

FIBROTIC FEATURES IN THE EOSINOPHILIC ESOPHAGITIS ENDOSCOPIC REFERENCE SCORE IN THE DIAGNOSIS AND RESPONSE TO PROTON-PUMP INHIBITOR THERAPY
FIBROTIC FEATURES IN THE EOSINOPHILIC ESOPHAGITIS ENDOSCOPIC REFERENCE SCORE IN THE DIAGNOSIS AND RESPONSE TO PROTON-PUMP INHIBITOR THERAPY

Alfredo J. Lucendo  et al.

COLONIC EPITHELIAL BRUSH BORDER ALTERATIONS IN MICROSCOPIC COLITIS: AN INTEGRATED MULTI-OMIC ANALYSIS
COLONIC EPITHELIAL BRUSH BORDER ALTERATIONS IN MICROSCOPIC COLITIS: AN INTEGRATED MULTI-OMIC ANALYSIS

Alfredo J. Lucendo  et al.

INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU
INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU

Alfredo J. Lucendo  et al.

BISMUTH QUADRUPLE REGIMEN WITH TETRACYCLINE OR DOXYCYCLINE VERSUS PYLERA® AS THIRD-LINE RESCUE THERAPY FOR H. PYLORI INFECTION: A PROSPECTIVE MULTICENTER ANALYSIS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE REGIMEN WITH TETRACYCLINE OR DOXYCYCLINE VERSUS PYLERA® AS THIRD-LINE RESCUE THERAPY FOR H. PYLORI INFECTION: A PROSPECTIVE MULTICENTER ANALYSIS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY
COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY

Alfredo J. Lucendo  et al.

ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS DURING THE PERIOD 2013-2022: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS DURING THE PERIOD 2013-2022: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Alfredo J. Lucendo  et al.

Item 21 - 40 / 69
1
2
3 4